title: Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
abstract: BACKGROUND
  In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC).
  
  
  METHODS
  Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated.
  
  
  RESULTS
  Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55-81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival.
  
  
  CONCLUSIONS
  The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.
authors.affiliation: 1] Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain [2] Department of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Prat
authors.affiliation: Department of Medical Oncology and Department of Pathology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Lluch
authors.affiliation: 1] Department of Medical Oncology, Hospital del Mar, IMIM, 08003 Barcelona, Spain [2] Department of Medical Oncology, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Albanell
authors.affiliation: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
authors.forename: W T
authors.initials: WT
authors.lastname: Barry
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
authors.forename: C
authors.initials: C
authors.lastname: Fan
authors.affiliation: Department of Medical Oncology, Hospital Virgen de la Salud, 45004 Toledo, Spain.
authors.forename: J I
authors.initials: JI
authors.lastname: Chacón
authors.affiliation: 1] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA [2] Department of Genetics, University of North Carolina, Chapel Hill, NC 27519, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Parker
authors.affiliation: Department of Medical Oncology, Complexo Hospitalario Universitario de A Coruña, 15002 A Coruña, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Calvo
authors.affiliation: Department of Medical Oncology, Onkologikoa, 20014 San Sebastián, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Plazaola
authors.affiliation: Department of Medical Oncology, Consorci Sanitari de Terrassa, 08225 Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Arcusa
authors.affiliation: Department of Medical Oncology, Corporació Sanitària Parc Taulí, 08208 Sabadell, Spain.
authors.forename: M A
authors.initials: MA
authors.lastname: Seguí-Palmer
authors.affiliation: Department of Medical Oncology and Department of Pathology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
authors.forename: O
authors.initials: O
authors.lastname: Burgues
authors.affiliation: Department of Medical Oncology and Department of Pathology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain.
authors.forename: N
authors.initials: N
authors.lastname: Ribelles
authors.affiliation: Department of Medical Oncology, Hospital General de Elche, 03203 Alicante, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Rodriguez-Lescure
authors.affiliation: Department of Medical Oncology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Guerrero
authors.affiliation: Department of Medical Oncology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Ruiz-Borrego
authors.affiliation: Department of Medical Oncology, Hospital Universitario La Fe, 46026 Valencia, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Munarriz
authors.affiliation: Department of Medical Oncology, Hospital San Camilo, 28006 Madrid, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: López
authors.affiliation: Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Adamo
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
authors.forename: M C U
authors.initials: MC
authors.lastname: Cheang
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Hu
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Gulley
authors.affiliation: Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Vidal
authors.affiliation: Alliance Statistical and Data Center, Duke University, Durham, NC 27708, USA.
authors.forename: B N
authors.initials: BN
authors.lastname: Pitcher
authors.affiliation: Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Liu
authors.affiliation: ProHEALTH Care Associates, LLP, Lake Success, NY 11803, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Citron
authors.affiliation: Department of Oncology, Washington University, St. Louis, MO 63130, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Ellis
authors.affiliation: Department of Oncology, Washington University, St. Louis, MO 63130, USA.
authors.forename: E
authors.initials: E
authors.lastname: Mardis
authors.affiliation: Department of Oncology, Washington University, St. Louis, MO 63130, USA.
authors.forename: T
authors.initials: T
authors.lastname: Vickery
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Hudis
authors.affiliation: Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: E P
authors.initials: EP
authors.lastname: Winer
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Carey
authors.affiliation: GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Caballero
authors.affiliation: GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Carrasco
authors.affiliation: 1] GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain [2] Department of Medical Oncology, Instituto de Investigación Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, 28007 Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Martín
authors.affiliation: 1] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA [2] Department of Genetics, University of North Carolina, Chapel Hill, NC 27519, USA [3] Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27519, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Perou
authors.affiliation: Department of Medical Oncology and Department of Pathology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Alba
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000970:Antineoplastic Agents
references.citation: JAMA. 2011 May 11;305(18):1873-81
references.pmid: 21558518
references.citation: J Clin Oncol. 2003 Apr 15;21(8):1431-9
references.pmid: 12668651
references.citation: Clin Cancer Res. 2007 Apr 15;13(8):2329-34
references.pmid: 17438091
references.citation: Breast Cancer Res Treat. 2012 Aug;135(1):301-6
references.pmid: 22752290
references.citation: J Clin Oncol. 2012 Jun 1;30(16):1996-2004
references.pmid: 22508827
references.citation: J Clin Oncol. 2015 Jan 1;33(1):13-21
references.pmid: 25092775
references.citation: Lancet Oncol. 2010 Aug;11(8):718-9; author reply 720-1
references.pmid: 20688274
references.citation: BMC Med Genomics. 2012 Oct 04;5:44
references.pmid: 23035882
references.citation: Breast Cancer Res. 2011 Apr 01;13(2):105
references.pmid: 21457488
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5351-61
references.pmid: 20829329
references.citation: Clin Cancer Res. 2014 Feb 15;20(4):782-90
references.pmid: 24536073
references.citation: Breast Cancer Res. 2010;12(1):R5
references.pmid: 20064235
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4236-44
references.pmid: 16896004
references.citation: Mol Oncol. 2011 Feb;5(1):5-23
references.pmid: 21147047
references.citation: J Natl Cancer Inst. 2011 Feb 2;103(3):264-72
references.pmid: 21191116
references.citation: Breast Cancer Res Treat. 2012 Nov;136(2):487-93
references.pmid: 23053638
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: J Natl Cancer Inst. 2008 Jun 4;100(11):805-14
references.pmid: 18505968
references.citation: Breast Cancer Res. 2010;12(5):R68
references.pmid: 20813035
references.citation: Breast Cancer Res. 2009;11(2):R15
references.pmid: 19272155
references.citation: Natl Cancer Inst Monogr. 1971 Dec;34:2-14
references.pmid: 4946581
references.citation: J Natl Cancer Inst. 2009 May 20;101(10):736-50
references.pmid: 19436038
references.citation: Breast Cancer Res. 2011 Mar 02;13(2):R22
references.pmid: 21366896
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5367-74
references.pmid: 15328174
references.citation: Genome Biol. 2003;4(5):P3
references.pmid: 12734009
references.citation: Breast Cancer Res. 2011 Oct 06;13(5):R97
references.pmid: 21978456
references.citation: BMC Cancer. 2011 Nov 14;11:486
references.pmid: 22081974
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1160-7
references.pmid: 19204204
references.citation: Lancet Oncol. 2014 Jun;15(7):747-56
references.pmid: 24794243
references.citation: J Clin Oncol. 2013 Jan 10;31(2):203-9
references.pmid: 23233704
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5222-32
references.pmid: 20837693
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: J Clin Oncol. 2007 Jan 1;25(1):118-45
references.pmid: 17159189
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1145-53
references.pmid: 20100965
references.citation: Clin Cancer Res. 2013 Sep 1;19(17):4889-99
references.pmid: 23780888
references.citation: Nat Rev Cancer. 2006 Feb;6(2):99-106
references.pmid: 16491069
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2784-95
references.pmid: 20404251
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references.pmid: 18250347
references.citation: J Clin Invest. 2011 Jul;121(7):2750-67
references.pmid: 21633166
references.citation: Nature. 2012 Apr 18;486(7403):346-52
references.pmid: 22522925
references.citation: Clin Cancer Res. 2013 Oct 1;19(19):5533-40
references.pmid: 23948975
references.citation: Oncologist. 2013;18(2):123-33
references.pmid: 23404817